The Incremental Prognostic Value of Baseline (18)F-FDG PET/CT Imaging in Angioimmunoblastic T-Cell Lymphoma

METHODS: From January 2010 to October 2019, a total of 23 patients who pathologically confirmed to have AITL were retrospectively analyzed. All patients underwent whole-body (18)F-FDG PET/CT scan before chemotherapy. The (18)F-FDG PET/CT features, clinical data, laboratory indicators, Ki67 labeling index, and survival status were collected and analyzed. RESULTS: The median follow-up was 22 months. The expected 1-, 2-, and 3-year survival rate was 72.2%, 49.6%, and 42.5%, respectively. The median overall survival (OS) was 23 months (95% confidence interval (CI): 8.459~37.541). AITL is prone to extranodal infiltration, in addition to nodal infiltration (6 patients had nodal infiltration alone, and 17 patients had both nodal and extranodal infiltration). The SUV(max) of nodal lesions were higher than that for the extranodal lesions (10.43 ± 4.45, 6.64 ± 3.51, F = 2.78, t = 4.39, P < 0.01). On multivariate survival analysis, the Eastern Cooperative Oncology Group (ECOG) and SUV(max) of extranodal lesions were independent predictors of OS. CONCLUSION: Baseline (18)F-FDG PET/CT results and SUV(max) of extranodal lesions showed an incremental prognostic value in addition to clinical prognostic factors.